Teva’s asthma candidates successful in three late-stage studies; regulatory … – Seeking Alpha

Teva's asthma candidates successful in three late-stage studies; regulatory
Seeking Alpha
Top-line results from three Phase 3 clinical trials assessing Teva Pharmaceutical Industries' (TEVA +0.4%) fluticasone propionate/salmeterol, a combination inhaled corticosteroid and long-acting beta agonist delivered via a multidose dry powder inhaler

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.